12/18
04:25 pm
qncx
Quince Therapeutics files for $200M mixed securities shelf [Seeking Alpha]
High
Report
Quince Therapeutics files for $200M mixed securities shelf [Seeking Alpha]
12/18
08:07 am
qncx
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $9.00 price target on the stock.
Medium
Report
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $9.00 price target on the stock.
11/13
04:05 pm
qncx
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
High
Report
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
11/12
04:05 pm
qncx
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Medium
Report
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
11/11
04:05 pm
qncx
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Medium
Report
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
11/7
08:36 am
qncx
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.
Medium
Report
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.
10/30
06:47 am
qncx
Quince Therapeutics, Inc. (NASDAQ: QNCX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Low
Report
Quince Therapeutics, Inc. (NASDAQ: QNCX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
10/29
08:00 am
qncx
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $11.00 price target on the stock.
Medium
Report
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $11.00 price target on the stock.
10/23
07:59 am
qncx
Quince Therapeutics, Inc. (NASDAQ: QNCX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
Quince Therapeutics, Inc. (NASDAQ: QNCX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
10/14
04:05 pm
qncx
Quince Therapeutics to Participate at Upcoming Investor Conferences
Low
Report
Quince Therapeutics to Participate at Upcoming Investor Conferences